Introduction
Since the identification and subsequent isolation of H pylori in 1983 a considerable body of evidence has accumulated showing that H pylori is the principal cause of nonautoimmune gastritis and peptic ulcer. By 1994, the evidence was suYciently strong for the National Institutes of Health (NIH) consensus conference in the United States to recommend eradication of H pylori infection to prevent ulcer recurrence in all patients with documented peptic ulcer disease. The observation that eradication of H pylori cures peptic ulcer disease and that screening for H pylori infection may improve the diagnostic yield of endoscopy is leading to a major re-evaluation of the optimal management of patients with dyspepsia. 1 Prior to the first description of the 13/14 Carbon urea breath test ( 13/14 C-UBT), the diagnosis of H pylori infection had usually been established by histology, culture or biopsy urease test or non-invasively by serology. Detection of H pylori by ELISA serology reflects only previous exposure to H pylori and may not indicate active or current infection. In addition because antibody titres can take up to six months to fall after successful treatment, ELISA tests cannot readily be used to assess the eYcacy of new treatment regimens or novel antimicrobial agents specifically developed for the treatment of H pylori infection.
2 The development of the 13/14 C-UBT as a simple, practical, highly accurate non-invasive test for H pylori infection is reflected in its increasingly important role in the management of dyspepsia. This review will consider some of the recent developments in the methodology and application of the 13/14 C-UBT.
Principles of the

13/14
C-UBT The 13/14 C-UBT exploits the copious amounts of urease produced by H pylori which hydrolyses urea to form ammonia and soluble carbon dioxide which is expired in the exhaled breath. Labelling of urea with either isotope allows the 13/14 CO 2 to be detected in the expired breath. 13 C is always measured as a ratio of 13 C to 12 C ( 13 CO 2 per mil), therefore the amount of excreted CO 2 does not need to be measured and a 10 ml tube of expired air suYces for analysis. When H pylori is present, the relative amount of 13 CO 2 increases considerably, and often exceeds that in the calibration standard, which is why results of the 13 C-UBT are expressed as the "excess" 13 CO 2 per mil. 3 14 CO 2 is measured using scintigraphy which is simple and relatively cheap but may be more inconvenient, especially since its use is restricted in some European countries if stable isotopic equivalents are available. 4 Although the radiation exposure of a single breath test is equivalent to only one day's background dose, patients must still have the risks explained. Some patients with chronic lung disease may be unable to provide suYcient CO 2 to change the colour of the trapping solution, in which case the 13 C-UBT provides a useful alternative. Most of the validation studies and assessments of new methodologies for the UBT have been done using 13 C-UBT, although some reports have also studied the
Methodology
PATIENT RELATED FACTORS
Urease producing oropharyngeal bacteria may rarely cause false positive results if breath samples are taken within 10 minutes of urea administration; false negative 13/14 C-UBT results will arise if tests are done in patients taking antibiotics, bismuth salts or more rarely taking proton pump inhibitors or sucralfate (which reduce the extent of antral H pylori infection). Patients should stop taking these drugs at least 10 days before undergoing a UBT. Many 13 C-UBT protocols require patients to fast for at least four hours but recently several groups have shown that fasting is no longer necessary if using the 13 C-UBT and a protocol which includes a test meal.
5-7 UBT RELATED FACTORS
Test meal
The test meal delays gastric emptying to maximise the gastric residence time, and exposure of the organism, to labelled urea, thereby allowing the dose of isotope to be reduced and increasing the sensitivity of the test. Citric acid, which delays gastric emptying via pH, or nutrition supplements (for example, Pulmicore, or Calogen), which delay gastric emptying via lipid content, are often used as test meals for the UBT.
A citric acid test meal may decrease oral urease activity but at the same time increase the discrimination between positive and negative A recent study suggested that citric acid, by increasing the extent of excess 13 CO 2 excretion, was the optimal test meal for the 13 C-UBT, but no results from uninfected patients were presented. 10 In addition, the extent to which citric acid increased the excess 13 CO 2 excretion was diYcult to judge as the breath test values are reported as proportional values above control (baseline) excess 13 CO 2 values. However any test meal which is proved to delay gastric emptying can be used providing it is palatable (the poor palatability of citric acid improves with orange juice), cheap, has a long shelf half-life, does not impair the dispersion of 13 C-urea or contribute in itself to excess 13 CO 2 excretion.
Quantity and formulation of urea
Although the amount of 13 C-urea now used is less than half that originally proposed by Graham, the quantity of substrate must be suYcient to saturate the enzyme. The specific activity of H pylori urease is similar to that of other bacteria but is produced over-abundantly and has a high binding aYnity for urea. 11 With purified 13 C-urea, the urease is fully saturated at the dose of 13 C-urea (100 mg) currently used, in contrast to 14 C-urea which should be used with cold urea to ensure full saturation of the enzyme. Lower doses of 13 C-urea (75 mg) have been incorporated into several commercial kits (many which may have been incompletely validated) but may be associated with false negative results (Perri F, personal communication).
Without a test meal, 13/14 C-urea in solution rapidly empties from the stomach, often within 10 minutes and breath samples taken after this initial period may give false negative results.
Recent reports have shown that a test meal is not needed if 13 C-urea is given in a capsule specially coated to disintegrate within minutes of entering the stomach. Consequently there is no 13 C-urea hydrolysis by oropharyngeal urease, so that in uninfected patients, the small increase in excess 13 CO 2 excretion normally seen after swallowing a solution of 13 C-urea, is almost completely abolished. 12 This may improve the accuracy of the test by reducing levels of excess 13 CO 2 excretion in uninfected patients to almost zero. In addition without the hydrolysis from oropharyngeal urease, breath samples may be taken sooner, thereby reducing the time taken to perform the test. It is also possible that this approach will allow the quantity of isotope to be lowered, further reducing the overall cost of the test.
Measurement of
CO 2 and analysis of results
The major disadvantage to the 13 C-UBT is the cost of 13 CO 2 analysis. Without the economies of scale and volume, purchase of a gas chromatography/isotope ratio mass spectrometry (GC/IRMS) unit is generally uneconomical, but samples can be sent for analysis by post to a commercial stable isotope laboratory. Although the cost of 13 C detection by GC/ IRMS has been falling, it is still the major factor limiting more widespread use of the 13 C-UBT. Several alternative methods for the detection of 13 CO 2 have recently been described, including the use of laser or infra-red spectroscopy. [13] [14] [15] These new technologies are still at an early stage of development and studies of their accuracy are limited, but they promise to enhance considerably the use of the 13 C-UBT, so that it can be done in most hospitals or specialist clinics.
The cut oV value for the 13 C-UBT was originally determined as 5.0 per mil based on the normal distribution of excess 13 CO 2 values for H pylori negative subjects who have never been infected. However, a recent re-analysis of data from several large clinical trials of H pylori eradication have allowed construction of receiver operator characteristic curves (ROCs) to set the optimum cut oV value according to sensitivity and specificity. On the basis of ROC analysis, a cut oV value of 3.5 per mil excess 13 CO 2 improves the sensitivity and specificity to 98.5% and 97.0%, respectively, although in clinical practice, and in contrast to the 14 C-UBT, less than 0.1% of 13 C-UBT results fall between 3.5-5 per mil. 16 17 The accuracy of the 13/14 C-UBT is supported by well designed studies which have shown the 13/14 C-UBT to have a sensitivity and specificity of >95%. Less encouraging results reported in early studies are likely to have arisen from the poor sensitivity of the endoscopic biopsy tests to which the C-UBT can be used to screen dyspeptic patients prior to endoscopy and to assess the eYcacy of H pylori eradication therapy. However the 13 C-UBT can also be used to detect infection in children, to measure suppression and clearance of infection in phase I and II trials, for epidemiological research and as a near patient test in primary care.
SCREENING BEFORE ENDOSCOPY
Several studies have suggested that noninvasive tests for H pylori can be used to screen young dyspeptic patients prior to endoscopy, although the most appropriate subsequent management strategy for these patients is as yet unclear and may vary from country to country.
1 18 19 However a study from Glasgow which used the 14 C-UBT to screen dyspeptic patients, found the prevalence of peptic ulcer in infected patients was 59%, with a positive predictive value high enough for it alone to be recommended as a screening test for ulcer disease. 20 
ASSESSING ERADICATION OF INFECTION
The 13/14 C-UBT is the best method of following patients in whom eradication of H pylori is being attempted. The test can clearly identify patients successfully treated and detect those in whom treatment has not been successful more easily and at an earlier stage than other tests for H pylori. Because eradication of H pylori is associated with resolution of histological gastritis and prevention of relapse of duodenal ulcer, the 13/14 C-UBT can be used as the sole method of follow up.
Using well validated protocols the sensitivity and specificity of the 13 C-UBT 4-6 weeks after the end of therapy has been found to be >95% and 96% respectively. There are fewer longer follow up studies, although, those using the European Standard 13 C-UBT protocol have shown >99% concordance between a 13 C-UBT and biopsy based tests at one year after treatment. 21 Unfortunately other 13/14 C-UBT studies from the United States with apparently minor protocol variations resulted in poorer sensitivity and specificity values when assessing eradication. In single dose or short term treatment studies the extent of suppression can allow diVerences between anti-H pylori drugs to be rapidly and easily assessed. By performing serial 13 C-UBTs the rate of recurrence of H pylori infection after diVerent treatments can also be determinedfor example, showing that, regardless of the preceding length of treatment with bismuth, H pylori infection recurs within days of finishing therapy. C-UBT is ideally suited for the determination of H pylori status in children, although until very recently there was a paucity of adequate data to validate its routine use. [23] [24] [25] As the endogenous CO 2 excretion by small children is much less than in adults, less urea is required and for children below the age of 8. Adult breath sampling is feasible for children over 3 years, but a mask may be required to collect expired breath samples from younger children.
Applications of the
Epidemiological research
A very important advantage of the 13 C-UBT over the 14 C-UBT is that it can be used for epidemiological studies, particularly in children, where in contrast to serological methods, the 13 C-UBT detects active infection, rather than previous exposure. Recently several studies have been performed using the 13 C-UBT in an attempt to document possible routes of transmission of H pylori between children. 26 27 Conclusions The C-UBT detects much lower levels of H pylori infection and by assessing the entire gastric mucosa avoids the risks of sampling error. The 13/14 C-UBT is a practical and readily available test providing a "gold standard" against which other tests for H pylori can be compared. The recent development of encapsulated 13 C urea and cheaper methods of 13 CO 2 analysis allow the duration of the test and costs to be reduced, and may herald a more widespread clinical application of this useful test 
